Why Cathie Wood is Buying These 2 High-Potential Stocks (And You Should Too?)

Cathie Wood’s Strategic Moves: Why Rubrik and Prime Medicine Caught Her Eye

Cathie Wood, the founder of ARK Invest, has built a reputation for identifying high-growth companies that are reshaping industries through innovation. Her investment strategy is centered on long-term value creation, focusing on disruptive technologies like artificial intelligence, genomics, robotics, and blockchain. When she adds a stock to her portfolio, it often signals strong potential. In early September, Wood added two notable names—Rubrik (RBRK) and Prime Medicine (PRME)—to her ETFs, sparking interest among investors.

These additions are not random; they reflect a deeper analysis of each company’s strengths and alignment with emerging trends. Let’s explore why these two growth stocks have caught Wood’s attention and whether they could be worth considering for your portfolio.

Why Rubrik Fits Into Cathie Wood’s Investment Philosophy

On September 10, the ARK Next Generation Internet ETF (ARKW) acquired 66,836 shares of Rubrik for $6.6 million, bringing its total investment in the company to $35 million. This represents 1% of the ETF’s overall portfolio. Rubrik, valued at $15.2 billion, specializes in data security, backup, recovery, and cloud-based protection. With ransomware and data breaches on the rise, the demand for robust cybersecurity solutions continues to grow.

Rubrik’s performance has been impressive, with a 17% year-to-date gain compared to the broader market. The company has shown strong growth in subscription and recurring revenue, which is a key indicator for growth investors. In Q2, Rubrik reported over $1.25 billion in annual recurring revenue (ARR), up 36% year-over-year. Cloud ARR specifically surged 57% to $1.1 billion, highlighting the adoption of Rubrik Security Cloud.

Despite being a fast-growing cloud company, profitability remains a challenge. However, the company has made progress, with adjusted net loss narrowing to $0.03 from $0.40 in the same period last year. Adjusted gross margin improved to 82%, and free cash flow rose to $57.5 million from a negative $32 million. Rubrik’s balance sheet is also strong, with $1.5 billion in cash and marketable securities.

Analysts predict significant growth ahead, with revenue expected to increase by 39.2% in 2025 and 25% in 2026. Wall Street analysts overwhelmingly favor Rubrik, with 18 out of 21 rating it a “Strong Buy.” The average target price is $114.95, suggesting substantial upside potential.

Why Prime Medicine Aligns With Wood’s Vision

Prime Medicine, a biotechnology company focused on gene-editing therapies using its Prime Editing technology, was another addition to ARK’s Genomic Revolution ETF (ARKG). On September 10, the ETF added 230,755 shares of Prime Medicine, increasing its total investment to $19 million. This makes it the ETF’s 19th largest holding, accounting for 1.9% of the portfolio.

Valued at $697.7 million, Prime Medicine is developing treatments for liver diseases, lung diseases, immune disorders, cancer, and rare conditions. Its stock has gained 32.9% year-to-date, outperforming the broader market. A key milestone came in Q2 when the company announced positive Phase 1/2 results for chronic granulomatous disease (CGD), providing the first clinical evidence that Prime Editing can restore immunological function in humans.

Although the company posted a net loss of $52.6 million in Q2, it ended the quarter with $115.4 million in cash and equivalents. With support from the Cystic Fibrosis Foundation, Prime Medicine is well-positioned to continue its research and development into 2027.

The company’s Prime Editing platform is designed to address a wide range of genetic mutations with precision, opening the door for applications in immunological disorders, cancers, and even common diseases. For investors willing to take on risk, Prime Medicine represents a high-potential opportunity in the field of genetic medicine.

Wall Street analysts rate Prime Medicine as a “Moderate Buy,” with eight out of 13 analysts giving it a “Strong Buy” rating. The average target price is $6.50, with some analysts projecting a potential rally of up to 150.6%.

Final Thoughts

Both Rubrik and Prime Medicine represent compelling opportunities for investors looking to capitalize on growth and innovation. While each carries its own risks, their alignment with major trends—cybersecurity and gene editing—makes them attractive options for those willing to embrace long-term value creation. As Cathie Wood continues to invest in these companies, it may be worth keeping a close eye on their future performance.